drugset / Trial / NCT05155189

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

NCT05155189

Phase 1 Recruiting 72 enrolled Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.

Timeline

Start
2022-02-21
Primary completion
2026-05
Completion
2041-05

Drugs

EvaluationDrugModalityDoseRoute
Subject C-CAR031 Cell therapy Intravenous
Subject Durvalumab Monoclonal antibody
Subject Lenvatinib Small molecule
Subject Regorafenib Small molecule